

# Dilip Shanghvi

Sun House, Plot No. 201 B/1, Western Express Highway,  
Goregaon (E), Mumbai - 400 063. Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324

April 11, 2023

National Stock Exchange of India Ltd.,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

BSE Limited,  
Market Operations Department  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

NSE Code: SUNPHARMA

BSE Code: 524715

Dear Sir / Madam,

**Sub: a) Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**b) Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

- a) Please find enclosed herewith the disclosure of shareholding in Sun Pharmaceutical Industries Limited (“Target Company”) as on March 31, 2023, in terms of regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in the prescribed format.
- b) I, Dilip S. Shanghvi, promoter of the Target Company hereby declare that, as on March 31, 2023, I along with Promoter Group and Persons acting in concert has not made any encumbrance, directly or indirectly, on the shares of the Target Company, other than those already disclosed during the financial year.

This is for your information and record.

Thanking you,

Yours faithfully,

---

**Dilip S. Shanghvi**

**Encl:** As above

**Copy to:** The Company Secretary,  
Sun Pharmaceutical Industries Limited,  
SPARC, Tandalja,  
Vadodara – 390 012  
Gujarat, India.

The Audit Committee  
Sun Pharmaceutical Industries Limited,  
SPARC, Tandalja,  
Vadodara – 390 012  
Gujarat, India.